Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Sep 28, 2008; 14(36): 5584-5589
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584
Fecal marker | Patients | PPV (95% CI) | NPV (95% CI) |
FC | All n = 371 | 30 (13-53) | 100 (77-100) |
FC | UC n = 27 | 38 (13-65) | 100 (71-100) |
FC | CD n = 101 | 14 (2-58) | 100 (30-100) |
MPO | All n = 371 | 23 (10-42) | 100 (59-100) |
MPO | UC n = 27 | 27 (10-50) | 100 (48-100) |
MPO | CD n = 101 | 12 (2-53) | 100 (19-100) |
EPX | All n = 371 | 22 (8-42) | 90 (56-98) |
EPX | UC n = 27 | 25 (8-49) | 85 (42-98) |
EPX | CD n = 101 | 14 (3-58) | 100 (30-100) |
- Citation: Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589
- URL: https://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.5584